Table 3.

Prevalence per 100 and 95% CIs for the use of six* selected psychotropic drugs during the year 2000

	US (n = 127,157)			Netherlands (n = 110,944)			Germany (n = 356,520)
	Male	Female	Total*	Male	Female	Total*	Male	Female	Total*
Alpha-Agonist	0.74	0.18	0.47	0.07	0.02	0.05	0	0	0
	0.62–0.86	0.14–0.22	0.43–0.51	0.05–0.1	0.01–0.03	0.03–0.07	0–0.01	0–0.3	0–0.03
Lithium	0.18	0.13	0.15	0	0.01	0.01	0	0	0
	0.08–0.25	0.06–0.21	0.07–0.23	0–0.02	0–0.02	0–0.02	0–0	0–0.01	0–0.1
Anxiolytic	0.51	0.47	0.49	0.65	0.81	0.73	0.4	0.42	0.41
	0.46–0.58	0.41–0.54	0.42–0.55	0.6–0.74	0.74–0.92	0.68–0.81	0.36–0.44	0.38–0.46	0.38–0.44
Hypnotic	0.15	0.17	0.16	0.35	0.32	0.33	0.08	0.11	0.09
	0.12–0.2	0.14–0.21	0.14–0.21	0.31–0.41	0.27–0.4	0.3–0.39	0.07–0.09	0.1–0.14	0.07–0.13
Antiparkinsonian	0.07	0.04	0.05	0.01	0.01	0.01	0.01	0.01	0.01
	0.03–0.09	0.01–0.07	0.02–0.07	0–0.02	0–0.02	0.01–0.02	0.01–0.02	0–0.02	0.0–0.02
ATC-MS	1.03	0.49	0.77	0.36	0.38	0.37	0.39	0.37	0.38
	0.94–1.12	0.42–0.54	0.72–0.84	0.32–0.42	0.32–0.43	0.33–0.41	0.37–0.43	0.35–0.41	0.37–0.41

*Of the 9 classes comprising “any psychotropic prevalence”. Data on antipsychotics, stimulants and antidepressants are shown in Tables 4, 5 and 6, respectively.

*Totals were adjusted to the child and adolescent population of the US 2000 census by the direct standardization method.